Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...
Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...
The Hollywood star sat down with Newsweek to discuss his next big project: upping enrollment in clinical trials.
Eli Lilly (LLY) and Walmart (WMT) announced a partnership to expand access to Zepbound (tirzepatide) through LillyDirect’s ...
Eli Lilly said federal regulators have approved of a single-injection, once-monthly maintenance regimen in the U.S. for its ulcerative colitis treatment Omvoh.
Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus ...
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...
Indian pharma giant Cipla on Thursday announced an agreement with US pharmaceutical firm Eli Lilly, acquiring the rights to ...
Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will ...
On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...
After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback